Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance

被引:91
作者
Elgendy, Sara M. [1 ,2 ]
Alyammahi, Shatha K. [1 ,2 ]
Alhamad, Dima W. [1 ,2 ]
Abdin, Shifaa M. [1 ,3 ]
Omar, Hany A. [1 ,2 ]
机构
[1] Univ Sharjah, Sharjah Inst Med Res, Sharjah 27272, U Arab Emirates
[2] Univ Sharjah, Coll Pharm, Sharjah 27272, U Arab Emirates
[3] Univ Sharjah, Coll Med, Sharjah 27272, U Arab Emirates
关键词
Ferroptosis; Cancer stem cells; Cancer resistance; NRF2; YAP/TAZ; CD44; Autophagy; EPITHELIAL-MESENCHYMAL TRANSITION; ERASTIN-INDUCED FERROPTOSIS; HIPPO PATHWAY; PROSPECTIVE IDENTIFICATION; THERAPEUTIC IMPLICATIONS; REGULATES FERROPTOSIS; CYSTEINE DIOXYGENASE; TUMOR; IRON; DEATH;
D O I
10.1016/j.critrevonc.2020.103095
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resistance to chemotherapeutic agents remains a major challenge in the fierce battle against cancer. Cancer stem cells (CSCs) are a small population of cells in tumors that possesses the ability to self-renew, initiate tumors, and cause resistance to conventional anticancer agents. Targeting this population of cells was proven as a promising approach to eliminate cancer recurrence and improve the clinical outcome. CSCs are less susceptible to death by classical anticancer agents inducing apoptosis. CSCs can be eradicated by ferroptosis, which is a non-apoptotic-regulated mechanism of cell death. The induction of ferroptosis is an attractive strategy to eliminate tumors due to its ability to selectively target aggressive CSCs. The current review critically explored the crosstalk and regulatory pathways controlling ferroptosis, which can selectively induce CSCs death. In addition, successful chemotherapeutic agents that achieve better therapeutic outcomes through the induction of ferroptosis in CSCs were discussed to highlight their promising clinical impact.
引用
收藏
页数:12
相关论文
共 188 条
[1]   Cancer Stem Cells: The Promise and the Potential [J].
Ajani, Jaffer A. ;
Song, Shumei ;
Hochster, Howard S. ;
Steinberg, Ira B. .
SEMINARS IN ONCOLOGY, 2015, 42 :S3-S17
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]   EMT: 2016 [J].
Angela Nieto, M. ;
Huang, Ruby Yun-Ju ;
Jackson, Rebecca A. ;
Thiery, Jean Paul .
CELL, 2016, 166 (01) :21-45
[4]   Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion [J].
Angeli, Jose Pedro Friedmann ;
Krysko, Dmitri, V ;
Conrad, Marcus .
NATURE REVIEWS CANCER, 2019, 19 (07) :405-414
[5]   Ferumoxytol for the treatment of iron deficiency anemia [J].
Auerbach, Michael ;
Chertow, Glenn M. ;
Rosner, Mitchell .
EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (10) :829-834
[6]   Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells [J].
Basu-Roy, Upal ;
Bayin, N. Sumru ;
Rattanakorn, Kirk ;
Han, Eugenia ;
Placantonakis, Dimitris G. ;
Mansukhani, Alka ;
Basilico, Claudio .
NATURE COMMUNICATIONS, 2015, 6
[7]   Iron addiction: a novel therapeutic target in ovarian cancer [J].
Basuli, D. ;
Tesfay, L. ;
Deng, Z. ;
Paul, B. ;
Yamamoto, Y. ;
Ning, G. ;
Xian, W. ;
McKeon, F. ;
Lynch, M. ;
Crum, C. P. ;
Hegde, P. ;
Brewer, M. ;
Wang, X. ;
Miller, L. D. ;
Dyment, N. ;
Torti, F. M. ;
Torti, S. V. .
ONCOGENE, 2017, 36 (29) :4089-4099
[8]   Cancer stem cells revisited [J].
Batlle, Eduard ;
Clevers, Hans .
NATURE MEDICINE, 2017, 23 (10) :1124-1134
[9]   Bioactive lipids in cancer stem cells [J].
Begicevic, Romana-Rea ;
Arfuso, Frank ;
Falasca, Marco .
WORLD JOURNAL OF STEM CELLS, 2019, 11 (09) :693-704
[10]   ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance [J].
Begicevic, Romana-Rea ;
Falasca, Marco .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11)